You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
30 December 2020
Alliance Pharma has strengthened its consumer healthcare presence in the US by acquiring Biogix, including its Amberen brand, for USD110 million in cash.
24 September 2020
Alliance Pharma has divided its product portfolio into Consumer Healthcare brands and Prescription Medicines. The company said the Consumer Healthcare business generated sales of GBP43.8 million (USD55.8 million) in the first half of 2020, representing 67% of its total sales.
24 September 2020
Alliance Pharma remains keen to build its consumer healthcare presence through acquisitions, according to chief executive officer Peter Butterfield.
24 July 2020
Alliance Pharma reported sales down by 7% in the first half of 2020 as its prescription medicines business was affected by the COVID-19 pandemic. The UK-based company said sales of its consumer healthcare products “continued to be robust”.
25 March 2020
Alliance Pharma and Church & Dwight have issued statements on the potential financial impact of the COVID-19 pandemic.
23 January 2020
Alliance Pharma is “well placed to selectively add to its portfolio”, according to chief executive officer Peter Butterfield, who says the UK-based company is focusing on “augmenting its consumer brands in international markets”.
26 July 2019
Ipsen has reported results for the first half of 2019, Alliance Pharma has released a trading update, and Novartis intends to keep its Sandoz generics business.
1 July 2019
Alliance Pharma, Pfizer and the German Medicines Manufacturers' Association, the BAH, have all recently announced people changes.